4 transcripts
AORT
Earnings call transcript
NYSE
2024 Q2
8 Aug 24
compared to $45.9 million in the second quarter of 2023, representing 320 basis points of leverage. R&D expenses for the second quarter were $7.5
AORT
Earnings call transcript
NYSE
2024 Q1
6 May 24
to $45.2 million in the first quarter of 2023, representing 500 basis points of leverage.
R&D expenses for the first quarter were $6.9 million compared
AORT
Earnings call transcript
NYSE
2023 Q4
15 Feb 24
for Endospan, these two products will significantly increase our addressable market opportunity. Lastly, on our R&D pipeline, our third-generation Frozen
AORT
Earnings call transcript
NYSE
2023 Q2
3 Aug 23
million in the second quarter of 2022.
R&D expenses for the second quarter were $7.4 million compared to $8.6 million in the second quarter of 2022
- Prev
- 1
- Next